Biocent Scientific India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 53.82%
(FY 2022)
- Profit 87.85%
(FY 2022)
- Ebitda 24.74%
(FY 2022)
- Net Worth 88.12%
(FY 2022)
- Total Assets 18.55%
(FY 2022)
About Biocent Scientific India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Preeti Mathew, Stelinpullamkottu Mathai, and Vijo Thomas serve as directors at the Company.
- CIN/LLPIN
U24290KL2016PTC047256
- Company No.
047256
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Nov 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Biocent Scientific India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijo Thomas  | Managing Director | 11-Nov-2016 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Preeti Mathew | Director | 11-Nov-2016 | Current |
| Stelinpullamkottu Mathai | Director | 11-Nov-2016 | Current |
Financial Performance of Biocent Scientific India.
Biocent Scientific India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 53.82% increase. The company also saw a substantial improvement in profitability, with a 87.85% increase in profit. The company's net worth Soared by an impressive increase of 88.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biocent Scientific India?
In 2022, Biocent Scientific India had a promoter holding of 98.00% and a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Renauxe Pharma India Private LimitedActive 14 years 8 monthsPreeti Mathew and Stelinpullamkottu Mathai are mutual person
- Westler Lifescience India Private LimitedActive 6 years 1 month
Stelinpullamkottu Mathai is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biocent Scientific India?
Unlock and access historical data on people associated with Biocent Scientific India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocent Scientific India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocent Scientific India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
